NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Stock Profit Turn Faces ZORYVE Concentration Question
Arcutis Biotherapeutics slipped about 2.5% today to US$26.43, even though the company just turned in what many biotech investors look for most. The dermatology specialist posted Q2 net product revenue of US$129.9m and reported US$15m of net income. That short term pullback sits against a bigger picture of rising revenue guidance for 2026 and a stock that had gained roughly 25% over the past three months. The rest of this earnings breakdown focuses on how durable that profit turn and growth...